Vancouver, BC – October 10, 2017 - InMed Pharmaceuticals Inc. (“InMed” or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce the addition of Dr. Mauro Maccarrone to its Scientific Advisory Board.
Dr. Mauro Maccarrone is Professor and Chair of Biochemistry and Molecular Biology at Campus Bio-Medico, University of Rome. He also serves as Director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. Prof. Maccarrone served as the President of the International Cannabinoid Research Society and was the recipient of their 2016 Mechoulam Award. He also served as Chair of the 2015 Gordon Research Conference on Cannabinoid Function in the CNS, and is a founding member of the European Cannabinoid Research Alliance. In addition to having authored over 460 published papers. Dr. Maccarrone serves as referee or on the editorial boards to numerous scientific journals, including Science, Nature Medicine, JAMA, PNAS, Blood, Brain, Journal of Neuroscience, Frontiers in Molecular Neuroscience, Cannabinoids and Cannabinoid Research. He is also Editor of Biochemistry for the Encyclopedia of Life Sciences.
“InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs. One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their in-depth knowledge to help advance our products,” said Dr. Sazzad Hossain, InMed’s Chief Scientific Officer. “We are very pleased to add Dr. Mauro Maccarrone and his vast experience in the field of cannabinoid research as an integral part of our Scientific Advisory Board. We look forward to working with Dr. Maccarrone to help bring drug therapies to those in need.”
Dr. Maccarrone added, “It is with pleasure that I accepted the invitation of InMed to join its Scientific Advisory Board to begin a new collaboration that will be a mutually beneficial endeavor and expand my own research horizons. Together with InMed’s scientific team, we are looking forward to shortening the path from basic science to tomorrow’s medicine on a number of innovative projects”.
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing innovative drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc.
Investor Relations and Corporate Development
Forward Looking Statements
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about developing industry-leading products in diseases with high unmet medical needs; working with Dr. Maccarrone to help bring drug therapies to those in need; shortening the path from basic science to tomorrow’s medicine on a number of innovative projects; and the expected fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Dr. Maccarrone’s continued availability; positive drug development results; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Dr. Maccarrone may become unwilling or unable to remain on the Scientific Advisory Board; technological challenges associated with developing InMed’s proprietary platform technology, including its bioinformatics database drug/disease targeting tool, its cannabinoid biosynthesis technology, and its drug product candidates which may not, individually and in aggregate, return their expected level of value; InMed may not be able to find suitable partners; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.